From Our Partners
Monday, June 27, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

Inovio’s Universal H1N1 Influenza Vaccine Phase I Results

by Global Biodefense Staff
April 18, 2013

InfluenzaInovio Pharmaceuticals, Inc. announced today that its universal H1N1 influenza vaccine, designed to protect against a spectrum of viral strains, generated protective antibody levels comparable to a current FDA-approved seasonal influenza vaccine against a currently circulating influenza strain.

The current FDA-approved trivalent influenza vaccines are designed to protect against only the three strains included in their formulation and are therefore incapable of addressing the inevitable and frequent shift and drift of influenza viral strains that can occur from season to season.

However, scientists have questioned whether an influenza vaccine designed to be broadly protective against multiple, unmatched influenza virus strains could provide the same level of protection as the currently licensed trivalent vaccines that are typically matched to two different influenza A strains and a single influenza B strain.

Inovio’s 100 patient phase I study for the SynCon universal vaccine showed a response rate comparable to that seen in volunteers who received the matched seasonal influenza vaccine.

“We couldn’t be more pleased with the results from this proof-of-principle and dose-finding study of our H1N1 universal influenza vaccine,” said Dr. J. Joseph Kim, Inovio’s President and CEO. “These results further support our mission to develop a universal influenza vaccine capable of providing years of true preemptive protection across subtypes and strains.”

Kim added that the results will also help the company fine-tune dosing for their pandemic avian H5N1 program and support research for the rapidly emerging H7N9 virus.

The results of the SynCon H1N1 Vaccine phase 1 study were presented today at the World Vaccine Congress in Washington, DC, by Dr. Niranjan Sardesai, Inovio’s Chief Operating Officer.

Read more about the study results at Inovio: Broadly targeted SynCon H1N1 vaccine induces protective antibodies comparable to current seasonal vaccine against currently circulating influenza strain.

From Our Partners
Tags: Avian InfluenzaH1N1InfluenzaVaccines

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC